Actinogen XanaMIA ACW0009 Phase 2b Trial for MCI and Mild Alzheimer's Disease

Who Can Participate

• Age and Gender: Male or female, aged 50 years or older
• Diagnosis: Must be diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer’s disease
• Study Partner: Must have an identified, reliable study partner
• Medication: If using medications for Alzheimer’s disease symptoms, doses must be stable for at least 3 months prior to screening

Trial Details

• Duration: 9 months
• Visits: Week 1, 2, 4, 8, 12, 16, 20, 24, 36, safety follow-up (10 site visits) + 2 telephone call visits
• Medication: Oral tablet once a day
• Placebo: 50% chance of receiving a placebo

For further information, interested individuals can contact Paula Mather, Clinical Trial Coordinator, at Ph: 08 9389 6433 or Email: aarfctd@alzheimersresearch.org.au.